CVS tops quarterly estimates, reaffirms profit outlook as turnaround plan takes effect

Core Insights - CVS Health reported fourth-quarter earnings and revenue that exceeded estimates, reaffirming its 2026 profit guidance, indicating progress in its turnaround plan [1][2] Financial Performance - The company expects full-year profit between $7 to $7.20 per share, aligning with analyst expectations of $7.17 per share [2] - CVS reported net income of $2.92 billion, or $2.30 per share, for the fourth quarter, compared to $1.62 billion, or $1.30 per share, for the same period last year [6] - Adjusted earnings were $1.09 per share, surpassing the expected $0.99 [7][8] - Revenue for the fourth quarter was $105.69 billion, an 8.2% increase from the previous year, exceeding expectations of $103.59 billion [7][8] Strategic Guidance - CVS maintains its 2026 revenue guidance of at least $400 billion, with analysts projecting $409.77 billion, although this may not fully account for headwinds [2][3] - The guidance includes $20 billion in headwinds, primarily from exiting the Affordable Care Act individual exchange market and adjustments in retail drug prices due to recent pharmaceutical agreements [3] Business Developments - CVS is accepting discount cards from the TrumpRx platform, aiming to reduce costs for eligible patients, and sees this as an opportunity for Caremark to negotiate lower costs [4] - The company anticipates growth driven by the recovery of its Aetna insurance business and the performance of Caremark [4] - Oak Street Health is improving profitability after CVS closed 16 underperforming locations, and the retail pharmacy business benefits from technological investments and acquisitions from Rite Aid [5] Market Response - Investors have responded positively to CVS's restructuring efforts, resulting in a stock rise of approximately 40% over the past year [6]